MHY5535, a novel PPARα antagonist, sensitizes ovarian cancer stem cells to chemotherapy by disrupting fatty acid oxidation-dependent mitochondrial metabolism
{{output}}
Ovarian cancer stem cells (CSCs) drive chemoresistance and tumor relapse through metabolic adaptability and enhanced mitochondrial function. Emerging evidence implicates peroxisome proliferator-activated receptor α (PPARα) as a critical regulator of CSC meta... ...
